Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
CAMBRIDGE, Mass. & HONG KONG & SHANGHAI & FLORHAM PARK, N.J.–(BUSINESS WIRE)–Epizyme, Inc. (Epizyme) (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, and HUTCHMED (China)…
